Plus Therapeutics to Present ReSPECT-GBM Clinical Trial Data at the 2021 SNO Annual Meeting (GlobeNewswire) - Sep 30, 2021 - "Plus Therapeutics, Inc....announced it will present interim data on Rhenium-186 NanoLiposome (186RNL) from its ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day being held November 18-21, 2021 in Boston, Massachusetts."
P1 data • Brain Cancer • Glioblastoma • Glioma • Oncology
|